Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice

DNA Repair

Volumn 5, Issue 7, 2006, Pages 852-859

  Reliene, Ramune ^a   Schiestl, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Ataxia telangiectasia; ATM; Chemoprevention; Lymphoma; N acetyl cysteine

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ATM PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; LIFESPAN; LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; ATAXIA TELANGIECTASIA;

EID: 33745263216     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2006.05.003     Document Type: Article

References (77)

1. Lavin M.F., and Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 15 (1997) 177-202
2. Meyn M.S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 55 (1999) 289-304
3. Chun H.H., and Gatti R.A. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amsterdam) 3 (2004) 1187-1196
4. Morrell D., Cromartie E., and Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77 (1986) 89-92
5. Taylor A.M., Metcalfe J.A., Thick J., and Mak Y.F. Leukemia and lymphoma in ataxia telangiectasia. Blood 87 (1996) 423-438
6. Xu Y. ATM in lymphoid development and tumorigenesis. Adv. Immunol. 72 (1999) 179-189
7. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D.A., Smith S., Uziel T., Sfez S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1753
8. Keith C.T., and Schreiber S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270 (1995) 50-51
9. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
10. Lavin M.F., Birrell G., Chen P., Kozlov S., Scott S., and Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat. Res. 569 (2005) 123-132
11. Gropp A., and Flatz G. Chromosome breakage and blastic transformation of lymphocytes in ataxia-telangiectasia. Humangenetik 5 (1967) 77-79
12. Cohen M.M., Shaham M., Dagan J., Shmueli E., and Kohn G. Cytogenetic investigations in families with ataxia-telangiectasia. Cytogenet. Cell Genet. 15 (1975) 338-356
13. Stumm M., Neubauer S., Keindorff S., Wegner R.D., Wieacker P., and Sauer R. High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia and Nijmegen breakage syndrome. Cytogenet. Cell Genet. 92 (2001) 186-191
14. Taylor A.M., Harnden D.G., Arlett C.F., Harcourt S.A., Lehmann A.R., Stevens S., and Bridges B.A. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258 (1975) 427-429
15. Gatti R.A. The inherited basis of human radiosensitivity. Acta Oncol. 40 (2001) 702-711
16. Cohen M.M., and Simpson S.J. The effect of bleomycin on DNA synthesis in ataxia telangiectasia lymphoid cells. Environ. Mutagen. 4 (1982) 27-36
17. Shiloh Y., Tabor E., and Becker Y. The response of ataxia-telangiectasia homozygous and heterozygous skin fibroblasts to neocarzinostatin. Carcinogenesis 3 (1982) 815-820
18. Morris C., Mohamed R., and Lavin M.F. DNA replication and repair in ataxia telangiectasia cells exposed to bleomycin. Mutat. Res. 112 (1983) 67-74
19. Barzilai A., Rotman G., and Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amsterdam) 1 (2002) 3-25
20. Reichenbach J., Schubert R., Schindler D., Muller K., Bohles H., and Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid. Redox Signal. 4 (2002) 465-469
21. Reichenbach J., Schubert R., Schwan C., Muller K., Bohles H.J., and Zielen S. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin. Exp. Immunol. 117 (1999) 535-539
22. Formichi P., Battisti C., Tripodi S.A., Tosi P., and Federico A. Apoptotic response and cell cycle transition in ataxia telangiectasia cells exposed to oxidative stress. Life Sci. 66 (2000) 1893-1903
23. Barlow C., Dennery P.A., Shigenaga M.K., Smith M.A., Morrow J.D., Roberts II L.J., Wynshaw-Boris A., and Levine R.L. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9915-9919
24. Kamsler A., Daily D., Hochman A., Stern N., Shiloh Y., Rotman G., and Barzilai A. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res. 61 (2001) 1849-1854
25. Quick K.L., and Dugan L.L. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann. Neurol. 49 (2001) 627-635
26. Gage B.M., Alroy D., Shin C.Y., Ponomareva O.N., Dhar S., Sharma G.G., Pandita T.K., Thayer M.J., and Turker M.S. Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress. Oncogene 20 (2001) 4291-4297
27. Reliene R., Fischer E., and Schiestl R.H. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 64 (2004) 5148-5153
28. Browne S.E., Roberts II L.J., Dennery P.A., Doctrow S.R., Beal M.F., Barlow C., and Levine R.L. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic. Biol. Med. 36 (2004) 938-942
29. Schubert R., Erker L., Barlow C., Yakushiji H., Larson D., Russo A., Mitchell J.B., and Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum. Mol. Genet. 13 (2004) 1793-1802
30. De Flora S., Izzotti A., D'Agostini F., and Balansky R.M. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22 (2001) 999-1013
31. Kelly G.S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 3 (1998) 114-127
32. Van Schooten F.J., Besaratinia A., De Flora S., D'Agostini F., Izzotti A., Camoirano A., Balm A.J., Dallinga J.W., Bast A., Haenen G.R., Van't Veer L., Baas P., Sakai H., and Van Zandwijk N. Effects of oral administration of N-acetyl-l-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 167-175
33. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., van Schayck C.P., Olivieri D., Del Donno M., De Backer W., Lankhorst I., and Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
34. Webb W.R. Clinical evaluaton of a new mucolytic agent, acetyl-cysteine. J. Thorac. Cardiovasc. Surg. 44 (1962) 330-343
35. Richardson P.S., and Phipps R.J. The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol. Ther. B 3 (1978) 441-479
36. Boman G., Backer U., Larsson S., Melander B., and Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. J. Respir. Dis. 64 (1983) 405-415
37. Prescott L.F., Park J., Ballantyne A., Adriaenssens P., and Proudfoot A.T. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 2 (1977) 432-434
38. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., Shiloh Y., Crawley J.N., Ried T., Tagle D., and Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
39. Liao M.J., Yin C., Barlow C., Wynshaw-Boris A., and van Dyke T. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol. Cell. Biol. 19 (1999) 3095-3102
40. Izzotti A., Balansky R.M., Cartiglia C., Camoirano A., Longobardi M., and De Flora S. Genomic and transcriptional alterations in mouse fetus liver after transplacental exposure to cigarette smoke. FASEB J. 17 (2003) 1127-1129
41. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., and Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10 (1996) 2411-2422
42. Petiniot L.K., Weaver Z., Barlow C., Shen R., Eckhaus M., Steinberg S.M., Ried T., Wynshaw-Boris A., and Hodes R.J. Recombinase-activating gene (RAG) 2-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6664-6669
43. De Flora S., Astengo M., Serra D., and Bennicelli C. Inhibition of urethan-induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett. 32 (1986) 235-241
44. Conaway C.C., Jiao D., Kelloff G.J., Steele V.E., Rivenson A., and Chung F.L. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett. 124 (1998) 85-93
45. D'Agostini F., Balansky R.M., Camoirano A., and De Flora S. Modulation of light-induced skin tumors by N-acetylcysteine and/or ascorbic acid in hairless mice. Carcinogenesis 26 (2005) 657-664
46. Spring K., Cross S., Li C., Watters D., Ben-Senior L., Waring P., Ahangari F., Lu S.L., Chen P., Misko I., Paterson C., Kay G., Smorodinsky N.I., Shiloh Y., and Lavin M.F. Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype. Cancer Res. 61 (2001) 4561-4568
47. Yan M., Kuang X., Qiang W., Shen J., Claypool K., Lynn W.S., and Wong P.K. Prevention of thymic lymphoma development in Atm-/- mice by dexamethasone. Cancer Res. 62 (2002) 5153-5157
48. Lavin M.F., and Spring K. Upregulation of FasL and apoptosis in thymic lymphomas in Atm knock-in mice. Toxicology 181-182 (2002) 483-489
49. Petiniot L.K., Weaver Z., Vacchio M., Shen R., Wangsa D., Barlow C., Eckhaus M., Steinberg S.M., Wynshaw-Boris A., Ried T., and Hodes R.J. RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Mol. Cell Biol. 22 (2002) 3174-3177
50. Borghesani P.R., Alt F.W., Bottaro A., Davidson L., Aksoy S., Rathbun G.A., Roberts T.M., Swat W., Segal R.A., and Gu Y. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3336-3341
51. Liyanage M., Weaver Z., Barlow C., Coleman A., Pankratz D.G., Anderson S., Wynshaw-Boris A., and Ried T. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood 96 (2000) 1940-1946
52. Zafarullah M., Li W.Q., Sylvester J., and Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 60 (2003) 6-20
53. Shibutani S., Takeshita M., and Grollman A.P. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349 (1991) 431-434
54. Rouet P., and Essigmann J.M. Possible role for thymine glycol in the selective inhibition of DNA synthesis on oxidized DNA templates. Cancer Res. 45 (1985) 6113-6118
55. Graziewicz M.A., Zastawny T.H., Olinski R., Speina E., Siedlecki J., and Tudek B. Fapyadenine is a moderately efficient chain terminator for prokaryotic DNA polymerases. Free Radic. Biol. Med. 28 (2000) 75-83
56. Kuzminov A. DNA replication meets genetic exchange: chromosomal damage and its repair by homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8461-8468
57. Michel B., Flores M.J., Viguera E., Grompone G., Seigneur M., and Bidnenko V. Rescue of arrested replication forks by homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8181-8188
58. Costanzo V., Robertson K., Bibikova M., Kim E., Grieco D., Gottesman M., Carroll D., and Gautier J. Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication. Mol. Cell 8 (2001) 137-147
59. Yan M., Qiang W., Liu N., Shen J., Lynn W.S., and Wong P.K. The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. FASEB J. 15 (2001) 1132-1138
60. Albini A., Morini M., D'Agostini F., Ferrari N., Campelli F., Arena G., Noonan D.M., Pesce C., and De Flora S. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 61 (2001) 8171-8178
61. Agarwal A., Munoz-Najar U., Klueh U., Shih S.C., and Claffey K.P. N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am. J. Pathol. 164 (2004) 1683-1696
62. Koster A., and Raemaekers J.M. Angiogenesis in malignant lymphoma. Curr. Opin. Oncol. 17 (2005) 611-616
63. Liu M., Wikonkal N.M., and Brash D.E. Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine. Carcinogenesis 20 (1999) 1869-1872
64. Goss P.E. New perspectives in the treatment of non-Hodgkin's lymphoma. Semin. Oncol. 19 (1992) 23-29
65. Keating M.J., McLaughlin P., and Cabanillas F. Low-grade non-Hodgkin's lymphoma-development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur. J. Cancer Care (Engl.) 6 (1997) 21-26
66. Greenstein S., Ghias K., Krett N.L., and Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin. Cancer Res. 8 (2002) 1681-1694
67. Doctrow S.R., Huffman K., Marcus C.B., Tocco G., Malfroy E., Adinolfi C.A., Kruk H., Baker K., Lazarowych N., Mascarenhas J., and Malfroy B. Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. J. Med. Chem. 45 (2002) 4549-4558
68. Melov S., Doctrow S.R., Schneider J.A., Haberson J., Patel M., Coskun P.E., Huffman K., Wallace D.C., and Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci. 21 (2001) 8348-8353
69. Liu R., Liu I.Y., Bi X., Thompson R.F., Doctrow S.R., Malfroy B., and Baudry M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8526-8531
70. Mitchell J.B., DeGraff W., Kaufman D., Krishna M.C., Samuni A., Finkelstein E., Ahn M.S., Hahn S.M., Gamson J., and Russo A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289 (1991) 62-70
71. Samuni A., Winkelsberg D., Pinson A., Hahn S.M., Mitchell J.B., and Russo A. Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage. J. Clin. Invest. 87 (1991) 1526-1530
72. Hahn S.M., Tochner Z., Krishna C.M., Glass J., Wilson L., Samuni A., Sprague M., Venzon D., Glatstein E., Mitchell J.B., et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 52 (1992) 1750-1753
73. Krishna M.C., and Samuni A. Nitroxides as antioxidants. Methods Enzymol. 234 (1994) 580-589
74. Krishna M.C., Russo A., Mitchell J.B., Goldstein S., Dafni H., and Samuni A. Do nitroxide antioxidants act as scavengers of O2- or as SOD mimics?. J. Biol. Chem. 271 (1996) 26026-26031
75. Branca M., Denurra T., and Turrini F. Reduction of nitroxide free radical by normal and G6PD deficient red blood cells. Free Radic. Biol. Med. 5 (1988) 7-11
76. May J.M., Qu Z.C., Juliao S., and Cobb C.E. Ascorbic acid decreases oxidant stress in endothelial cells caused by the nitroxide tempol. Free Radic. Res. 39 (2005) 195-202
77. Hahn S.M., Lepinski D.L., DeLuca A.M., Mitchell J.B., and Pellmar T.C. Neurophysiological consequences of nitroxide antioxidants. Can. J. Physiol. Pharmacol. 73 (1995) 399-403